A
Astrid Kiermaier
Researcher at Hoffmann-La Roche
Publications - 32
Citations - 1510
Astrid Kiermaier is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Pertuzumab & Trastuzumab. The author has an hindex of 12, co-authored 30 publications receiving 1140 citations. Previous affiliations of Astrid Kiermaier include MedStar Washington Hospital Center & Genentech.
Papers
More filters
Journal ArticleDOI
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem,Yung-Jue Bang,Feng Feng-yi,Jian M. Xu,Keun-Wook Lee,Shun-Chang Jiao,Jorge León Chong,Roberto I. López-Sanchez,Timothy J. Price,Oleg Gladkov,Oliver Stoss,Julie Hill,Vivian Ng,Michaela Lehle,Marlene Thomas,Astrid Kiermaier,Josef Rüschoff +16 more
TL;DR: All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially, and due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.
Journal ArticleDOI
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
José Baselga,Javier Cortes,Seock-Ah Im,Emma Clark,Graham Ross,Astrid Kiermaier,Sandra M. Swain +6 more
TL;DR: Through comprehensive prospective analyses, CLEOPATRA biomarker data demonstrate that HER2 is the only marker suited for patient selection for the trastuzumab plus pertuzumAB-based regimen in HER2-positive metastatic breast cancer.
Journal ArticleDOI
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Stephen J Luen,Roberto Salgado,Stephen B. Fox,Peter Savas,Jennifer Eng-Wong,Emma Clark,Astrid Kiermaier,Sandra M. Swain,José Baselga,Stefan Michiels,Sherene Loi +10 more
TL;DR: In patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab or placebo, higher TIL values are significantly associated with improved overall survival, suggesting that the effect of antitumour immunity extends to the advanced setting.
Journal ArticleDOI
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Sandra M. Swain,Michael S. Ewer,Giuseppe Viale,Suzette Delaloge,J-M Ferrero,Mark Verrill,Ramon Colomer,Cláudia Vieira,Theresa L. Werner,Hannah Douthwaite,Denise Bradley,M Waldron-Lynch,Astrid Kiermaier,Jennifer Eng-Wong,Chau T. Dang +14 more
TL;DR: Treatment with pertuzumab, trastuzumAB, and common anthracycline-containing regimens for the neoadjuvant treatment of early breast cancer resulted in cardiac and general safety profiles, and pCR rates, consistent with prior studies with pertizumab.
Journal ArticleDOI
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini,Astrid Kiermaier,Giulia Bianchi,Young-Hyuck Im,Tadeusz Pienkowski,Mei Ching Liu,Ling Ming Tseng,Mitch Dowsett,Lila Zabaglo,Sarah Kirk,Tania Szado,Jennifer Eng-Wong,Lukas C. Amler,Pinuccia Valagussa,Luca Gianni +14 more
TL;DR: Conventional HER2 assessment should continue and HER2 remains the only biomarker suitable for patient selection in this population, and PIK3CA exon 9 mutation to lack of sensitivity to HER2-targeted monoclonal antibody treatment, warrant further investigation.